🔗 Share this article

While the US undertakes historic changes to its immunization recommendations, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus shots during the pandemic and has focused upon alleged deaths after COVID-19 vaccination in her brief time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Program

Public health authorities were set to announce radical revisions to the childhood immunization program in December, synchronizing the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US out of step with much of the world with insufficient data for benefit. The announcement has been postponed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the gathering. She was just designated interim head of the FDA’s CDER, the fifth appointee to run the center this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the agency – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for ending certain childhood shot schedules in the US to become more like Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

In her initial comments, she has kept her attention on immunizations – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no apparent experience in drug development, approval processes or management, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the CDER, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a sizeable institution. She is not an expert in drug approvals.”

Former heads of CBER would “understand legal statutes and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who ran CBER have had.”

CDER has an vast portfolio at the agency, Woodcock stated.

“Many people just pays attention on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars division, OTC medication office and so forth, and every single one have to be supervised,” she explained. “The thing you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a major leadership element to the position, which supervises more than 5,000 personnel. “It is a huge leadership role, if you execute it properly,” Woodcock concluded.

Response and Contentious Initiatives

In response to inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a representative said that the “inquiries stem from incorrect premises”.

“Her resume matches the duties of her job,” the representative explained, noting the time Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's recently launched priority voucher program, a contentious expedited drug-approval program that allegedly troubled her former heads. “By what process are these therapies being selected for this voucher program? Who takes the decisions?” Howard questioned. “There is a lot of confidentiality going on at the agency right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards laxer oversight of most medications, aside from shots.”

Established History on Immunizations

With vaccines, Høeg has a more documented, if problematic, history, critics observe. She authored a study using unverified volunteer-provided data to determine the frequency of myocarditis after Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the current government featured revising guidelines for novel immunizations and halting “non-essential” immunizations, she remarked post-election on a audio program. At the FDA, Høeg has allegedly proposed barring young men from getting COVID-19 vaccinations.

“She’s an thorough dogmatist who begins with her preconceived notions and works backwards to fit the data in a highly deceptive, dishonest fashion,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|